Working Together Against Cancer
Collaborations – between scientists, among institutions, with patients and caregivers, and across traditional boundaries – are critically important to the discovery of innovative new methods to prevent, treat, and cure cancer.
It will take more than financial resources to achieve those goals. Imagine for a moment that money was not an obstacle and true collaboration against cancer could be achieved.
AACR strives to build such collaborations with cancer centers, medical institutions, organizations, researchers, and patients and their families worldwide – all with the single goal of defeating cancer. We are proud to work with organizations large and small to transform lives through research. Here are just a few examples of that work to nurture collaborations against cancer.
Hosted by the European Organization for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR), the Symposium brings together over 2,000 academics, scientists, and pharmaceutical industry representatives from across the globe to discuss innovations in drug development, target selection, and the impact of new discoveries in molecular biology.
During the last several years, numerous innovative agents have been discovered as a result of tremendous developments in our understanding of the molecular basis of cancer. Tremendous clinical progress in cancer treatment will be accomplished through the conduct of translational research projects, efficient new drug development, and the execution of large, prospective, randomized, multicenter cancer clinical trials. For these reasons, the symposium has been organized to ensure the maximum amount of interaction and discussion through a range of plenary sessions and workshops.
The driving force behind this collaboration among the Cancer Therapy & Research Center at UT Health Science Center San Antonio, the AACR, and Baylor College of Medicine is our shared goal to advance progress against breast cancer. As exciting strides are made in the field of breast cancer research and treatment, the Symposium presents essential up-to-the-minute information in a forum where the leading minds in the field are able to discuss advances in basic, translational, and clinical breast cancer research. The Symposium provides a vital forum in which a broad spectrum of researchers, health professionals, advocates, and others with a special interest in breast cancer interact, communicate, and learn from one another.
The AACR Science Series at the FDA sessions began in July 2012. This series brings scientific leaders to the FDA campus to present cutting-edge advances in cancer biology to FDA scientific review staff and to foster the development of relationships between FDA reviewers and external scientific experts.
In addition to highlighting findings first presented at the AACR Annual Meeting, distinguished AACR Members have discussed the latest research on the following topics: novel non-invasive techniques to detect and monitor tumors; targeting metabolic pathways in hematologic malignancies and solid tumors; rational strategies for developing BRAF inhibitors; and immunotherapies.
The AACR has teamed up with Lilly Oncology on The Hope Murals Project to celebrate 10 years of Lilly Oncology on Canvas, a way for those affected by cancer to tell their stories. Lilly's goal was to create 10 murals based on inspirational art from the Oncology on Canvas project in 10 cities across the country. Philadelphia was selected as a location for one of these murals. The subject of the Philadelphia Hope Mural is
Awakening, an artwork by a cancer patient and chosen by voters on the
Lilly Oncology on Canvas Facebook page.
In July 2013, the AACR and the Cancer Research Institute (CRI) unveiled a joint venture, the scientific journal
Cancer Immunology Research.
The journal publishes research articles reporting major advances in all areas of cancer immunology, including basic investigations in host–tumor interactions, developmental therapeutics in model systems, early translational studies in patients, and late-stage clinical trials.
“We are proud to launch this new journal that will further accelerate progress in cancer immunology and immunotherapy and enter into a new partnership with the Cancer Research Institute. By combining the longstanding commitment of CRI to tumor immunology with the breadth and depth of the AACR investment in all aspects of cancer biology,
Cancer Immunology Research will serve as a link between immunology and the larger cancer research community,” said Margaret Foti, PhD, MD (hc), chief executive officer of the AACR.
The AACR joins with the Personalized Medicine Coalition, Harvard Medical School, Harvard Business School, and Partners HealthCare Personalized Medicine to host the Personalized Medicine Conference. This conference brings together hundreds of leaders in the field of personalized medicine to share the latest findings in this burgeoning area of cancer care and medicine.
Find out more.